Trials / Active Not Recruiting
Active Not RecruitingNCT06502977
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Phase 2a Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of Tarlatamab in Chinese Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-307)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tarlatamab | IV infusion |
Timeline
- Start date
- 2024-08-27
- Primary completion
- 2025-03-28
- Completion
- 2027-01-08
- First posted
- 2024-07-16
- Last updated
- 2026-04-15
- Results posted
- 2026-04-15
Locations
12 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06502977. Inclusion in this directory is not an endorsement.